Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$52.50
$1.42(3.49%)
At close: 4:00 PM EDT
$52.50
$1.42(3.49%)
Day’s Range― - ―
52-Week Range$14.11 - $52.83
Previous CloseN/A
Volume230.44K
Average Volume (3M)404.29K
Market Cap
$2.46B
Enterprise Value$1.55K
Total Cash (Recent Filing)$436.08M
Total Debt (Recent Filing)$10.11M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 05, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding47,978,287
10 Day Avg. Volume321,428
30 Day Avg. Volume404,290
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$60.25Price Target Upside14.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
Early Revenue Traction And Strong Gross MarginEmerging revenue alongside very high gross profitability indicates potential for attractive economics if Rapport’s pipeline produces durable commercial or partnered revenue. The margin profile provides a strong foundation for future operating leverage once development spending moderates.
Low Leverage And Substantial Asset BaseMinimal debt relative to equity limits interest and refinancing pressure, while the sizable asset base provides financial capacity for continued clinical development. This conservative capital structure is a relative strength compared with more highly leveraged development-stage biotechs.
Governance ContinuitySuccessful director elections and auditor ratification preserve board and oversight continuity during a critical development phase. Stable governance can support consistent execution of the research strategy and reduce disruption as clinical programs advance.
Bears Say
Deep Operating LossesLarge losses show that current revenue is insufficient to offset research, development, and operating expenses. Until clinical programs mature or produce partnering or product revenue, continued losses will constrain earnings visibility and increase reliance on external funding.
Substantial Cash BurnPersistent cash outflows make funding availability a central business risk. Even if burn is stabilizing, the company must continue financing expensive clinical and discovery work, which can reduce financial flexibility and require additional capital before profitability.
Nascent Revenue And Financing DependenceThe limited commercial revenue base provides little evidence of recurring operating self-sufficiency. Rapport therefore remains dependent on equity or other financing, creating dilution risk and leaving long-term financial outcomes tied to clinical progress and future partnering opportunities.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $14.11 and its highest was $52.83 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $2.46B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.07.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -1.21.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,978,287 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$1.19 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 0.569%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.25 (14.76% Upside)
$60.25 (14.76% Upside)
Blogger Sentiment
Neutral
RAPP Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 197.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.77%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$60.25
▲(14.76% Upside)
Technical Analysis
Ownership Overview
22.31% Insiders
24.32% Mutual Funds
29.16% Other Institutional Investors
15.25% Public Companies and
Individual Investors